Helius Medical Technologies, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Helius Medical Technologies (Nasdaq: HSDT), a neurotech company focused on neurological wellness, has announced the approval of equity awards under its 2021 Inducement Plan. These awards, approved by independent directors on August 14, 2024, serve as material inducements for three new employees joining the company.
The equity awards, granted in accordance with Nasdaq Listing Rule 5635(c)(4), consist of options to purchase a total of 23,500 shares of the Company's Class A common stock. The options have an exercise price of $0.6802 per share, matching the closing price of Helius' common stock on the grant date. These options have a ten-year term and vest over four years, with 25% vesting annually, subject to continued employment and potential acceleration or forfeiture under certain conditions.
Helius Medical Technologies (Nasdaq: HSDT), un'azienda di neurotecnologie focalizzata sul benessere neurologico, ha annunciato l'approvazione di premi azionari nel quadro del suo Piano di Induzione 2021. Questi premi, approvati da direttori indipendenti il 14 agosto 2024, fungono da incentivi materiali per tre nuovi dipendenti che si uniscono all'azienda.
I premi azionari, concessi in conformità alla Regola di Listing Nasdaq 5635(c)(4), consistono in opzioni per l'acquisto di un totale di 23.500 azioni delle azioni ordinarie di Classe A della Società. Le opzioni hanno un prezzo di esercizio di $0,6802 per azione, corrispondente al prezzo di chiusura delle azioni ordinarie di Helius nella data di concessione. Queste opzioni hanno una scadenza di dieci anni e si maturano in quattro anni, con il 25% che matura annualmente, soggetto a continuazione dell'impiego e a potenziali accelerazioni o perdite in determinate condizioni.
Helius Medical Technologies (Nasdaq: HSDT), una empresa de neurotecnología centrada en el bienestar neurológico, ha anunciado la aprobación de premios de acciones bajo su Plan de Inducción 2021. Estos premios, aprobados por directores independientes el 14 de agosto de 2024, sirven como incentivos materiales para tres nuevos empleados que se unen a la empresa.
Los premios de acciones, otorgados de acuerdo con la Regla de Listado de Nasdaq 5635(c)(4), consisten en opciones para comprar un total de 23,500 acciones de acciones ordinarias Clase A de la Compañía. Las opciones tienen un precio de ejercicio de $0.6802 por acción, igualando el precio de cierre de las acciones ordinarias de Helius en la fecha de concesión. Estas opciones tienen un plazo de diez años y se consolidan en cuatro años, con un 25% consolidándose anualmente, sujeto a la continuación del empleo y a posibles aceleraciones o pérdidas bajo ciertas condiciones.
헬리우스 의료 테크놀로지스 (Nasdaq: HSDT), 신경 기술에 중점을 둔 신경학적 웰빙 회사가 2021년 유도 계획에 따라 주식 상여의 승인을 발표했습니다. 이 상여는 2024년 8월 14일에 독립 이사들이 승인한 것으로, 회사에 합류하는 세 명의 새로운 직원에 대한 물질적 유인으로 작용합니다.
주식 상여는 나스닥 상장 규칙 5635(c)(4)에 따라 부여되며, 회사의 클래스 A 보통주 23,500주를 구입할 수 있는 옵션으로 구성됩니다. 옵션의 행사 가격은 주당 $0.6802로, 부여일의 헬리우스 보통주 종가와 일치합니다. 이 옵션은 10년의 기간을 가지며 4년에 걸쳐 분할 성취되며, 매년 25%가 성취되며, 계속 근무와 특정 조건에 따른 가속화 또는 몰수 가능성에 따라 달라질 수 있습니다.
Helius Medical Technologies (Nasdaq: HSDT), une entreprise de neurotechnologie axée sur le bien-être neurologique, a annoncé l'approbation des attributions d'actions dans le cadre de son Plan d'Induction 2021. Ces attributions, approuvées par des administrateurs indépendants le 14 août 2024, servent d'incitations matérielles pour trois nouveaux employés rejoignant l'entreprise.
Les attributions d'actions, accordées conformément à la Règle de cotation Nasdaq 5635(c)(4), consistent en des options d'achat d'un total de 23 500 actions des actions ordinaires de Classe A de la Société. Les options ont un prix d'exercice de 0,6802 $ par action, correspondant au prix de clôture des actions ordinaires de Helius à la date d'attribution. Ces options ont une durée de dix ans et se vestissent sur quatre ans, avec 25 % se vestissant annuellement, sous réserve d'une poursuite d'emploi et d'une éventuelle accélération ou perte dans certaines conditions.
Helius Medical Technologies (Nasdaq: HSDT), ein Neurotech-Unternehmen, das sich auf neurologisches Wohlbefinden konzentriert, hat die Genehmigung von Aktienprämien im Rahmen seines Induktionsplans 2021 bekannt gegeben. Diese Prämien, die am 14. August 2024 von unabhängigen Direktoren genehmigt wurden, dienen als materielle Anreize für drei neue Mitarbeiter, die dem Unternehmen beitreten.
Die Aktienprämien, die gemäß der Nasdaq-Listing-Regel 5635(c)(4) gewährt werden, bestehen aus Optionen zum Kauf von insgesamt 23.500 Aktien der Stammaktien der Klasse A des Unternehmens. Die Optionen haben einen Ausübungspreis von $0,6802 pro Aktie, was dem Schlusskurs der Stammaktien von Helius am Zinstag entspricht. Diese Optionen haben eine Laufzeit von zehn Jahren und erlangen über vier Jahre hinweg, wobei 25% jährlich erworben wird, vorbehaltlich der Fortsetzung des Arbeitsverhältnisses sowie möglicher Beschleunigung oder Verfall unter bestimmten Bedingungen.
- Helius is attracting new talent with equity incentives, potentially strengthening its workforce
- The company is following Nasdaq listing rules, demonstrating regulatory compliance
- The equity awards may lead to potential dilution for existing shareholders
NEWTOWN, Pa., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that, effective August 14, 2024, its independent directors approved equity awards under Helius’ 2021 Inducement Plan, as a material inducement to three individuals entering into employment with the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder approved equity plan.
In connection with entering into employment with Helius, the three individuals, who were not previous employees or directors of Helius, received options to purchase an aggregate of 23,500 shares of the Company’s Class A common stock. The option awards have an exercise price of
About Helius Medical Technologies, Inc.
Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using an orally applied technology platform that amplifies the brain’s ability to engage physiologic compensatory mechanisms and promote neuroplasticity, improving the lives of people dealing with neurologic diseases. The Company’s first commercial product is the Portable Neuromodulation Stimulator. For more information about the PoNS® or Helius Medical Technologies, visit www.heliusmedical.com.
About the PoNS Device and PoNS Therapy
The Portable Neuromodulation Stimulator (PoNS) is an innovative, non-implantable, orally applied therapy that delivers neurostimulation through a mouthpiece connected to a controller and it’s used, primarily at home, with physical rehabilitation exercise, to improve balance and gait. The PoNS device, which delivers mild electrical impulses to the tongue, is indicated for use in the United States as a short-term treatment of gait deficit due to mild-to-moderate symptoms from multiple sclerosis (“MS”) and is to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only.
PoNS has shown effectiveness in treating gait or balance and a significant reduction in the risk of falling in stroke patients in Canada, where it received authorization for sale in three indications: (i) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from stroke and is to be used in conjunction with physical therapy; (ii) for use as a short-term treatment (14 weeks) of chronic balance deficit due to mild-to-moderate traumatic brain injury (“mmTBI”) and is to be used in conjunction with physical therapy; and (iii) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS and is to be used in conjunction with physical therapy. PoNS is also authorized for sale in Australia for short term use by healthcare professionals as an adjunct to a therapeutic exercise program to improve balance and gait. For more information visit www.ponstherapy.com.
Investor Relations Contact:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
FAQ
How many shares of Helius Medical Technologies (HSDT) were granted as options to new employees?
What is the exercise price of the options granted by Helius Medical Technologies (HSDT) on August 14, 2024?
What is the vesting schedule for the options granted by Helius Medical Technologies (HSDT)?
Under which plan did Helius Medical Technologies (HSDT) grant these equity awards?
